Search - tctmd.com

Displaying 341 - 360 of 584

Sort: Relevancy | Date

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Daily News

COVID-19 Drug Candidates May Raise Arrhythmia Risk

Caitlin E. Cox

April 03, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Shelley Wood

March 30, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Daily News

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

L.A. McKeown

March 25, 2020

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

L.A. McKeown

March 20, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Shelley Wood

March 04, 2020

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Shelley Wood

February 14, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Todd Neale

February 10, 2020

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

L.A. McKeown

January 17, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Aspirin Not Protective Against CVD in Black Patients

Caitlin E. Cox

December 18, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

Advertisement

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

COVID-19 Drug Candidates May Raise Arrhythmia Risk

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

Evinacumab Cuts LDL Cholesterol in Homozygous FH

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

Missed Opportunities: Many HF Patients Not Tested for CAD

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Aspirin Not Protective Against CVD in Black Patients

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content